SU1151193A3 - Способ получени перорального препарата дипиридамола - Google Patents

Способ получени перорального препарата дипиридамола Download PDF

Info

Publication number
SU1151193A3
SU1151193A3 SU823452105A SU3452105A SU1151193A3 SU 1151193 A3 SU1151193 A3 SU 1151193A3 SU 823452105 A SU823452105 A SU 823452105A SU 3452105 A SU3452105 A SU 3452105A SU 1151193 A3 SU1151193 A3 SU 1151193A3
Authority
SU
USSR - Soviet Union
Prior art keywords
dipyridamole
release
equivalents
mixed
per mole
Prior art date
Application number
SU823452105A
Other languages
English (en)
Russian (ru)
Inventor
Брикль Рольф
Грубер Петер
Шепки Готтфрид
Больцер Герхард
Original Assignee
Др.Карл Томэ Гмбх (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6134913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SU1151193(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Др.Карл Томэ Гмбх (Фирма) filed Critical Др.Карл Томэ Гмбх (Фирма)
Application granted granted Critical
Publication of SU1151193A3 publication Critical patent/SU1151193A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SU823452105A 1981-06-19 1982-06-17 Способ получени перорального препарата дипиридамола SU1151193A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813124090 DE3124090A1 (de) 1981-06-19 1981-06-19 Neue orale dipyridamolformen

Publications (1)

Publication Number Publication Date
SU1151193A3 true SU1151193A3 (ru) 1985-04-15

Family

ID=6134913

Family Applications (1)

Application Number Title Priority Date Filing Date
SU823452105A SU1151193A3 (ru) 1981-06-19 1982-06-17 Способ получени перорального препарата дипиридамола

Country Status (27)

Country Link
US (1) US4427648A (cg-RX-API-DMAC10.html)
EP (1) EP0068191B2 (cg-RX-API-DMAC10.html)
JP (1) JPS5849312A (cg-RX-API-DMAC10.html)
KR (1) KR880001090B1 (cg-RX-API-DMAC10.html)
AR (1) AR228779A1 (cg-RX-API-DMAC10.html)
AT (1) ATE17317T1 (cg-RX-API-DMAC10.html)
AU (1) AU555951B2 (cg-RX-API-DMAC10.html)
CA (1) CA1200496A (cg-RX-API-DMAC10.html)
DD (1) DD202505A5 (cg-RX-API-DMAC10.html)
DE (2) DE3124090A1 (cg-RX-API-DMAC10.html)
DK (1) DK158540C (cg-RX-API-DMAC10.html)
ES (1) ES8304797A1 (cg-RX-API-DMAC10.html)
FI (1) FI80829C (cg-RX-API-DMAC10.html)
GB (1) GB2101484B (cg-RX-API-DMAC10.html)
GR (1) GR76503B (cg-RX-API-DMAC10.html)
HU (1) HU186078B (cg-RX-API-DMAC10.html)
IE (1) IE53543B1 (cg-RX-API-DMAC10.html)
IL (1) IL66075A (cg-RX-API-DMAC10.html)
IN (1) IN158513B (cg-RX-API-DMAC10.html)
MA (1) MA19503A1 (cg-RX-API-DMAC10.html)
MX (1) MX160712A (cg-RX-API-DMAC10.html)
MY (1) MY8700727A (cg-RX-API-DMAC10.html)
NZ (1) NZ201008A (cg-RX-API-DMAC10.html)
PH (1) PH25637A (cg-RX-API-DMAC10.html)
PT (1) PT75077B (cg-RX-API-DMAC10.html)
SU (1) SU1151193A3 (cg-RX-API-DMAC10.html)
ZA (1) ZA824315B (cg-RX-API-DMAC10.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
DK0585355T3 (da) * 1991-05-20 1995-06-06 Tanabe Seiyaku Co Flerlagspræparat med reguleret frigivelse
US5302393A (en) * 1991-07-11 1994-04-12 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
DE19845358A1 (de) 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
JP2006524203A (ja) 2003-04-24 2006-10-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トロンビンの過剰形成及び／又はトロンビンレセプターの発現上昇により生じる血栓塞栓性疾病及び疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US20090048173A1 (en) * 2004-05-13 2009-02-19 Wolfgang Eisert Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
BG860Y1 (bg) * 2004-09-17 2007-02-28 "Софарма" Ад Лекарствена форма на дипиридамол
EP1863460B1 (en) 2005-03-22 2013-01-16 Losan Pharma GmbH Solubilized ibuprofen
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
RU2442574C2 (ru) * 2005-08-22 2012-02-20 Новартис Аг ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
ES2550035T3 (es) * 2006-01-27 2015-11-04 Adare Pharmaceuticals, Inc. Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
EP2387994A1 (en) * 2006-01-27 2011-11-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
AU2006337643A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Dipyridamole extended-release formulations and process for preparing same
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP2234963B1 (en) 2007-12-28 2020-04-08 Impax Laboratories, LLC Controlled release formulations of levodopa and uses thereof
WO2009097156A1 (en) * 2008-02-01 2009-08-06 Barr Laboratories, Inc. Pharmaceutical capsules comprising extended release dipyridamole pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
WO2010036975A2 (en) * 2008-09-25 2010-04-01 Teva Pharmaceutical Industries Ltd. Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US20110027771A1 (en) * 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
WO2012162492A1 (en) * 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CA2915445C (en) 2013-07-19 2024-04-23 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EA201992230A1 (ru) 2013-12-04 2020-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Улучшенные фармацевтические композиции пимобендана
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2157201C3 (de) * 1970-11-13 1974-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verbesserte feste orale Applikationsform von Raubasin
DE2700433A1 (de) * 1977-01-07 1978-07-20 Kali Chemie Pharma Gmbh Arzneimittelzubereitungen mit verbesserten resorptionseigenschaften
LU77353A1 (cg-RX-API-DMAC10.html) * 1977-05-16 1979-01-19
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
IE48715B1 (en) * 1978-12-22 1985-05-01 Elan Corp Plc New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same
DE3000979A1 (de) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS6116368A (ja) * 1984-07-02 1986-01-24 Mitsubishi Electric Corp 画像処理装置の検査装置

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
1. Выложенна за вка DE № 2831164, кл. А 61 К 9/28, 1980. *

Also Published As

Publication number Publication date
KR880001090B1 (ko) 1988-06-23
JPH0251402B2 (cg-RX-API-DMAC10.html) 1990-11-07
HU186078B (en) 1985-05-28
DK158540C (da) 1990-11-12
DD202505A5 (de) 1983-09-21
EP0068191B1 (de) 1986-01-08
GR76503B (cg-RX-API-DMAC10.html) 1984-08-10
GB2101484A (en) 1983-01-19
DK269682A (da) 1982-12-20
AU555951B2 (en) 1986-10-16
FI822173L (fi) 1982-12-20
FI80829C (fi) 1990-08-10
EP0068191A2 (de) 1983-01-05
NZ201008A (en) 1985-11-08
MA19503A1 (fr) 1982-12-31
EP0068191A3 (en) 1983-08-10
DE3124090C2 (cg-RX-API-DMAC10.html) 1991-11-21
CA1200496A (en) 1986-02-11
ES513235A0 (es) 1983-03-16
KR840000229A (ko) 1984-02-18
GB2101484B (en) 1984-09-19
FI80829B (fi) 1990-04-30
ES8304797A1 (es) 1983-03-16
AR228779A1 (es) 1983-04-15
FI822173A0 (fi) 1982-06-17
MX160712A (es) 1990-04-23
IL66075A0 (en) 1982-09-30
JPS5849312A (ja) 1983-03-23
US4427648A (en) 1984-01-24
EP0068191B2 (de) 1991-09-11
IE821453L (en) 1982-12-19
DK158540B (da) 1990-06-05
PH25637A (en) 1991-08-21
AU8496582A (en) 1982-12-23
PT75077A (de) 1982-07-01
IN158513B (cg-RX-API-DMAC10.html) 1986-11-29
MY8700727A (en) 1987-12-31
DE3124090A1 (de) 1983-01-05
ATE17317T1 (de) 1986-01-15
ZA824315B (en) 1984-02-29
DE3268380D1 (en) 1986-02-20
IL66075A (en) 1985-09-29
PT75077B (de) 1985-05-31
IE53543B1 (en) 1988-12-07

Similar Documents

Publication Publication Date Title
SU1151193A3 (ru) Способ получени перорального препарата дипиридамола
CA1228546A (en) Oral mopidamol preparations
AU611999B2 (en) Pharmaceutical granulate
US4916161A (en) Taste-masking pharmaceutical agents
CA1254143A (en) Pharmaceutical preparation with a content of ibuprofen, and process for its preparation
CA2375600A1 (fr) Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
NO312224B1 (no) Fremgangsmåter for fremstilling av farmasöytiske granuler og farmasöytiske formuleringer for anvendelse i behandling avbakterielle infeksjoner
US20020054911A1 (en) Novel oral dosage form for carvedilol
US6274168B1 (en) Phenytoin sodium pharmaceutical compositions
EA001537B1 (ru) Гранулят для получения быстрораспадающихся и быстрорастворяющихся композиций, содержащих большое количество лекарственного средства
CA1261260A (en) Directly compressible codeine salt compositions
SK3552003A3 (en) Ion-strength independent sustained release pharmaceutical formulation
CZ300908B6 (cs) Tableta obsahující levothyroxin natrium a zpusob její výroby
EP2902015B1 (en) Preparation method of agomelatine solid preparation
LT3527B (en) Tablets,process for preparing them, granulate and method for granulating
AU611740B2 (en) Pharmaceutical composition and process for its preparation
CN108324697B (zh) 一种含枸橼酸莫沙必利的胶囊剂及其制备方法
GB2151920A (en) Oral compositions containing sulpiride
JPH02286614A (ja) アセトアミノフェン製剤
KR101302810B1 (ko) 고형 의약 제제
JP3383600B2 (ja) 粉粒体乃至錠剤
FR2541576A1 (fr) Medicament contenant de la muzolimine et son procede de preparation
CZ20032119A3 (en) Pharmaceutical composition containing citalopram
US20070077294A1 (en) Capsules comprising topiramate
JPH06192093A (ja) 医薬組成物製造のための補助剤混合物と非固体活性化合物からの吸着体